Printer Friendly

ANERGEN NAMES HARRY H. PENNER JR. AND BRUCE L.A. CARTER TO BOARD OF DIRECTORS

 REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- Anergen Inc. (NASDAQ: ANRG) today announced that Harry H. Penner Jr. and Bruce L.A. Carter, Ph.D., have been named to the company's board of directors, bringing the total number of board members to six.
 Penner, 48, joined Anergen's board of directors as previously announced on Aug. 23, 1993, in conjunction with the research and development collaboration and equity investment agreement between Anergen and Novo Nordisk A/S (NYSE: NVO). He became president and chief executive officer of Neurogen Corp., a Branford, Conn.-based biotechnology company, on Dec. 1, 1993.
 "Mr. Penner brings years of expertise and solid legal and financial experience from the pharmaceutical industry to an emerging biotechnology company," said John W. Fara, Ph.D., Anergen's president and chief executive officer. "His involvement with and contribution to Anergen's board over the past months and his role at Neurogen made Mr. Penner an ideal board candidate," added Fara.
 Penner received a juris doctor degree from Fordham University and an LL.M. degree in international law from New York University. Penner is a member of the board of directors of Neurogen, the Biotechnology Industry Organization (BIO) and several other organizations. He has previously served on the boards of various biotechnology companies.
 Carter, 50, is president of ZymoGenetics Inc., a Seattle-based biotechnology company, and chief scientific officer of the healthcare group of Denmark-based pharmaceutical and bioindustrial company, Novo Nordisk A/S. Previously, Carter served as research director for ZymoGenetics and prior to that was the head of molecular genetics at G.D. Searle & Co. Ltd.
 "We are also pleased to have someone of Dr. Carter's stature joining our board of directors, and we look forward to many years of his advice and counsel as we progress as a biotechnology company," stated Fara.
 Carter received a Ph.D. in microbiology from Queens Elizabeth's College at the University of London. He is currently on the board of directors of the Virginia Mason Research Center and the Washington Technology Center, among others.
 Anergen is developing therapies for the treatment of autoimmune diseases using proprietary biopharmaceutical compounds designed to inactivate or anergize the disease-related T cells in the immune system that are responsible for each disease.
 -0- 1/12/94
 /CONTACT: Joan Shields, investor relations, of Anergen, 415-361-8901; or Mark J. Brand or Kim P. Feazle of Pondel Parsons & Wilkinson, 310-207-9300/
 (ANRG NVO)


CO: Anergen Inc. ST: California IN: MTC SU: PER

JL-JB -- LA009 -- 1288 01/12/94 09:01 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:413
Previous Article:PEER REVIEW ANALYSIS, INC. AUTHORIZES REORGANIZATION AGREEMENT WITH CORE MANAGEMENT, INC.
Next Article:FLEET CREDIT CORP. TRIPLES AIRCRAFT FINANCING VOLUME
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters